Gilead Sciences (GILD) is a publicly traded Healthcare sector company. As of May 20, 2026, GILD trades at $130.15 with a market cap of $160.99B and a P/E ratio of 17.61. GILD moved +0.10% today. Year to date, GILD is +10.47%; over the trailing twelve months it is +19.78%. Its 52-week range spans $82.82 to $157.29. Analyst consensus is strong buy with an average price target of $159.83. Rallies surfaces GILD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Gilead Sciences Prices $3 Billion Notes at 4.25%-4.90% Across Four Maturities: Gilead priced $3 billion of senior unsecured notes across four tranches: $500 M 4.25% due 2028, $1 B 4.40% due 2029, $1 B 4.60% due 2031 and $500 M 4.90% due 2034. Offering closes May 20, 2026, with proceeds for corporate purposes, including acquisitions and investments.
| Metric | Value |
|---|---|
| Price | $130.15 |
| Market Cap | $160.99B |
| P/E Ratio | 17.61 |
| EPS | $7.42 |
| Dividend Yield | 0.82% |
| 52-Week High | $157.29 |
| 52-Week Low | $82.82 |
| Volume | 3.70M |
| Avg Volume | 0 |
| Revenue (TTM) | $29.74B |
| Net Income | $9.22B |
| Gross Margin | 79.36% |
22 analysts cover GILD: 0 strong buy, 18 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $159.83.